Teacher Retirement System of Texas Buys 3,250 Shares of Xencor, Inc. (NASDAQ:XNCR)
Posted by MarketBeat News on Apr 1st, 2025 Teacher Retirement System of Texas boosted its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,645 shares of the biopharmaceutical company’s stock after purchasing an additional 3,250 shares during the period. Teacher Retirement System of Texas’ holdings in Xencor were worth $428,000 at the end of the most recent quarter. A number of other hedge funds have also recently added to or reduced their stakes in the stock. Maryland State Retirement & Pension System lifted its stake in shares of Xencor by 12.9% in the 4th quarter. Maryland State Retirement & Pension System now owns 23,567 shares of the biopharmaceutical company’s stock valued at $542,000 after acquiring an additional 2,686 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in Xencor by 5.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 122,897 shares of the biopharmaceutical company’s stock worth $2,824,000 after purchasing an additional 6,528 shares in the last quarter. Swiss National Bank raised its position in Xencor by 3.0% in the fourth quarter. Swiss National Bank now owns 123,600 shares of the biopharmaceutical company’s stock valued at $2,840,000 after purchasing an additional 3,600 shares during the last quarter. Amundi boosted its stake in shares of Xencor by 225.0% during the fourth quarter. Amundi now owns 35,380 shares of the biopharmaceutical company’s stock valued at $829,000 after purchasing an additional 24,494 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,337 shares during the last quarter. Wall Street Analyst Weigh In Several equities research analysts recently commented on XNCR shares. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Finally, Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.38. Check Out Our Latest Stock Analysis on XencorXencor Price Performance Shares of NASDAQ XNCR opened at $10.64 on Tuesday. The company has a market capitalization of $749.72 million, a PE ratio of -3.33 and a beta of 0.74. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a twelve month low of $10.40 and a twelve month high of $27.24. The firm has a fifty day simple moving average of $15.39 and a 200 day simple moving average of $20.01. Xencor (NASDAQ:XNCR – Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, sell-side analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year. About Xencor (Free Report) Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Featured Articles Five stocks we like better than Xencor What is diluted earnings per share (Diluted EPS)? 3 Buyable Stocks With Solid Bottoms Ready to Rebound What is the Nikkei 225 index? Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star 2 Fintech Stocks to Buy Now and 1 to Avoid Robotaxi News: What Tesla and Lyft Headlines Mean for Shares Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR – Free Report). Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEThrivent Financial for Lutherans Trims Stake in Veeco Instruments Inc. (NASDAQ:VECO) NEXT HEADLINE »Teacher Retirement System of Texas Purchases 39,933 Shares of Geron Co. (NASDAQ:GERN) You might be interested in: